Cargando…
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer
The aim of this study was to determine the maximum tolerated dose of a fixed dose of docetaxel when combined with continuous infusion ifosfamide, with and without G-CSF support, in the treatment of advanced cancer, and to evaluate anti-tumour activity of this combination. Thirty-one patients with ad...
Autores principales: | Marx, G, Lewis, C, Hall, K, Levi, J, Ackland, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376167/ https://www.ncbi.nlm.nih.gov/pubmed/12373597 http://dx.doi.org/10.1038/sj.bjc.6600542 |
Ejemplares similares
-
Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer
por: Kosmas, C, et al.
Publicado: (2003) -
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
por: Pronk, L. C., et al.
Publicado: (1998) -
Phase 1 study on docetaxel and ifosfamide in patients with advanced solid tumours
Publicado: (1998) -
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
por: del Muro, X García, et al.
Publicado: (2002) -
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)